Back to all bills
Standard Summary
Comprehensive overview in 1-2 paragraphs
Cameron's Law restores the orphan drug tax credit from 25% to 50% of qualified clinical testing expenses to incentivize development of treatments for rare diseases.
Key Points
- 1Increases orphan drug tax credit from 25% to 50% of qualified expenses
- 2Applies to taxable years beginning after enactment date
- 3Supports development of treatments for rare diseases affecting small patient populations
- 4Maintains existing eligibility requirements for orphan drug designation
- 5Aims to encourage pharmaceutical investment in rare disease treatments
Impact Areas
Pharmaceutical industryRare disease researchTax policyBiotechnology sectorPatients with rare diseases
Generated by kwaipilot/kat-coder-pro:free on Nov 21, 2025